Herm Rosenman Sells 16,530 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) Director Herm Rosenman sold 16,530 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total value of $4,132,500.00. Following the completion of the sale, the director directly owned 4,250 shares of the company’s stock, valued at approximately $1,062,500. The trade was a 79.55% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Natera Stock Performance

Shares of NTRA opened at $261.91 on Friday. The firm has a market cap of $37.51 billion, a PE ratio of -160.68 and a beta of 1.56. The firm’s 50 day moving average price is $212.73 and its 200 day moving average price is $215.87. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $271.47.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of NTRA. JPMorgan Chase & Co. grew its position in Natera by 10.5% during the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after acquiring an additional 1,225,420 shares during the last quarter. Wellington Management Group LLP boosted its stake in Natera by 94.7% in the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after purchasing an additional 2,420,263 shares in the last quarter. State Street Corp boosted its stake in Natera by 2.2% in the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock worth $545,624,000 after purchasing an additional 72,087 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Natera by 37.5% during the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock worth $428,987,000 after purchasing an additional 727,366 shares during the last quarter. Finally, Coatue Management LLC increased its stake in shares of Natera by 1,446.1% in the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after buying an additional 2,463,008 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

NTRA has been the topic of several analyst reports. JPMorgan Chase & Co. increased their target price on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Wall Street Zen lowered Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Wolfe Research started coverage on shares of Natera in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 target price on the stock. Evercore reissued an “outperform” rating and issued a $270.00 price target on shares of Natera in a report on Friday, May 8th. Finally, Wells Fargo & Company raised their price target on shares of Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $259.22.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.